Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 8/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.46 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.46 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 6/20 | 0.46 |
| ▸ | NPC1 | O15118 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.46 |
| ▸ | RECQL | P46063 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2984669 | 1.00 | ALDH1A1 (0.62) | ALDH1A1KDM4EKMT2AGAAMAPT | |
| SCHEMBL2196627 | 0.85 | ALDH1A1 (0.68) | ALDH1A1KDM4EKMT2AGAAMAPT | |
| SCHEMBL2196629 | 0.85 | ALDH1A1 (0.68) | ALDH1A1KDM4EKMT2AGAAMAPT | |
| SCHEMBL13992611 | 0.81 | ALDH1A1 (0.68) | ALDH1A1KDM4EKMT2AGAAMAPT | |
| SCHEMBL14007054 | 0.81 | ALDH1A1 (0.68) | ALDH1A1KDM4EKMT2AGAAMAPT | |
| SCHEMBL70027 | 0.78 | NPSR1 (0.67) | ALDH1A1KDM4EKMT2AMAPTHPGD | |
| SCHEMBL7476495 | 0.78 | ALDH1A1 (0.68) | ALDH1A1KDM4EKMT2AGAAMAPT | |
| SCHEMBL7476500 | 0.78 | ALDH1A1 (0.68) | ALDH1A1KDM4EKMT2AGAAMAPT | |
| SCHEMBL14007055 | 0.77 | NPSR1 (0.46) | ALDH1A1KDM4EKMT2AGAAMAPT | |
| SCHEMBL27848222 | 0.77 | MAPT (0.49) | ALDH1A1KDM4EKMT2AGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9725459-B2 | 3-oxo-tetrahydro-furo[3,2-B]pyrrol-4(5H)-yl) derivatives I | GRUNENTHAL GMBH (DE) | 2017-08-08 | — | — | US | disclosed |
| US-9725459-B2 | 3-oxo-tetrahydro-furo[3,2-B]pyrrol-4(5H)-yl) derivatives I | GRUNENTHAL GMBH (DE) | 2017-08-08 | — | — | US | disclosed |
| EP-3134414-A1 | 3-OXO-TETRAHYDRO-FURO[3,2-B]PYRROL-4(5H)-YL) DERIVATIVES II | Grünenthal GmbH (DE) | 2017-03-01 | — | — | EP | disclosed |
| EP-2482072-B1 | A PHOTOLUMINESCENT PROBE | UNIV TARTU (EE) | 2016-07-06 | — | — | EP | disclosed |
| WO-2015161924-A1 | 3-OXO-TETRAHYDRO-FURO[3,2-B]PYRROL-4(5H)-YL) DERIVATIVES II | Grünenthal GmbH (DE) | 2015-10-29 | — | — | WO | disclosed |
| WO-2015161928-A1 | 3-OXO-TETRAHYDRO-FURO[3,2-B]PYRROL-4(5H)-YL) DERIVATIVES I | Grünenthal GmbH (DE) | 2015-10-29 | — | — | WO | disclosed |
| US-20150307507-A1 | 3-OXO-TETRAHYDRO-FURO[3,2-B]PYRROL-4(5H)-YL) DERIVATIVES I | Grünenthal GmbH (DE) | 2015-10-29 | — | — | US | disclosed |
| US-20150307507-A1 | 3-OXO-TETRAHYDRO-FURO[3,2-B]PYRROL-4(5H)-YL) DERIVATIVES I | Grünenthal GmbH (DE) | 2015-10-29 | — | — | US | disclosed |
| US-20140057284-A1 | PHOTOLUMINESCENT MOLECULAR COMPLEX AND METHOD FOR DETERMINING OF THE CONCENTRATION OF SAID MOLECULAR COMPLEX | UNIVERSITY OF TARTU (EE) | 2014-02-27 | — | — | US | disclosed |
| EP-1831207-B1 | AMINOPYRIMIDINE COMPOUNDS AS PLK INHIBITORS | AMGEN INC (US) | 2012-11-14 | — | — | EP | disclosed |
| US-20080293716-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080293716-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080255120-A1 | SUBSTITUTED 2,5-HETEROCYCLIC DERIVATIVES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| CN-101115749-A | Aminopyrimidine compounds and methods of use | AMGEN INC (US) | 2008-01-30 | — | — | CN | disclosed |
| EP-1708697-A4 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2007-11-28 | — | — | EP | disclosed |
| EP-1831207-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2007-09-12 | — | — | EP | disclosed |
| US-20070185133-A1 | Aminopyrimidine compounds and methods of use | AMGEN, INC. (US) | 2007-08-09 | — | — | US | disclosed |
| EP-1708697-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-11 | — | — | EP | disclosed |
| WO-2006066172-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | AMGEN, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
| WO-2005074642-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293716-A1 | Chemical Compounds | CYP11B2, CYP11B1, REN | ALDH1A1 275/4885KDM4E 4493/4885KMT2A 4386/4885 |
| US-20150307507-A1 | 3-OXO-TETRAHYDRO-FURO[3,2-B]PYRROL-4(5H)-YL) DERIVATIVES I | CTSK, OPRK1, CAT | ALDH1A1 886/4885KDM4E 997/4885KMT2A 3210/4885 |
| US-20080255120-A1 | SUBSTITUTED 2,5-HETEROCYCLIC DERIVATIVES | CYP3A5, ABCG2, ABCB1 | ALDH1A1 297/4885KDM4E 2840/4885KMT2A 4030/4885 |
| US-20070185133-A1 | Aminopyrimidine compounds and methods of use | PLK1, TYMP, TK2 | ALDH1A1 1565/4885KDM4E 1956/4885KMT2A 1112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.